Alternatives to Sandostatin if You Can't Fill Your Prescription

If your pharmacy can't fill your Sandostatin (octreotide) prescription, you have options. Several clinically-validated alternatives exist in the same drug class, and your doctor can help you determine which one is most appropriate based on your condition, your current dose, and your insurance coverage.

This guide explains your main alternatives when Sandostatin is unavailable — whether temporarily out of stock or facing an extended shortage.

First Option: Bridge With Immediate-Release Octreotide Injection

If Sandostatin LAR Depot is the specific formulation you can't find, the first and most straightforward option is bridging with immediate-release (IR) subcutaneous octreotide. This is the same active ingredient — just a shorter-acting form.

Bridging typically involves 100–200 mcg subcutaneous injections 2–3 times daily, depending on your previous LAR dose and clinical response. The immediate-release formulation is available from multiple generic manufacturers — Avet, Fresenius Kabi, Hikma, and Sagent — and is significantly more widely stocked than LAR.

Pros: Same drug, same mechanism. Widely available. Easier to find.

Cons: Requires multiple daily injections instead of one monthly injection. Not ideal for long-term use if LAR is tolerated well.

Second Option: Switch to Generic Octreotide LAR (Teva)

If brand Sandostatin LAR Depot is unavailable, ask your pharmacy if Teva's generic octreotide for injectable suspension is in stock. The FDA approved Teva's generic in October 2024 — it's bioequivalent to Sandostatin LAR Depot, meaning it performs identically in the body. Some specialty pharmacies may have the Teva product when Novartis's brand is unavailable, or vice versa.

Pros: Same drug, same once-monthly dosing schedule. May be available when brand is not. Often lower cost — $3,000–$5,500/month vs. $6,700–$8,500/month for brand.

Cons: Teva's generic LAR has also faced supply constraints. May not be on formulary for all plans yet.

Third Option: Lanreotide (Somatuline Depot)

Lanreotide is the most commonly prescribed alternative when octreotide in any form is unavailable. Also a somatostatin analog, it works through the same mechanism — binding to somatostatin receptors to suppress hormone secretion.

Lanreotide (brand name Somatuline Depot) is FDA-approved for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. It's manufactured by Ipsen on a completely independent supply chain from octreotide — making it a reliable backup during octreotide shortages.

It comes as a prefilled syringe for deep subcutaneous injection every 4 weeks (60 mg, 90 mg, or 120 mg), which some patients prefer over the Sandostatin LAR pre-mix kit.

Pros: Independent supply chain, separate manufacturer. Once-monthly deep SC injection with prefilled syringe (easier to prepare). Comparable clinical evidence for acromegaly, carcinoid, and NETs.

Cons: Requires new prior authorization in most cases. Dose conversion from octreotide LAR to lanreotide is not a direct milligram-for-milligram switch — your doctor will guide the transition.

Fourth Option: Pasireotide LAR (Signifor LAR) — For Acromegaly Only

For patients with acromegaly who are not adequately controlled on first-generation somatostatin analogs — or for whom no other option is available — pasireotide LAR (Signifor LAR) is a second-generation option. It binds to a broader range of somatostatin receptors (SSTR1, 2, 3, and 5) compared to octreotide's primary SSTR2 binding.

Pros: May provide better biochemical control in patients who don't respond fully to octreotide or lanreotide. Once-monthly IM injection.

Cons: Significantly higher rate of hyperglycemia — requires additional blood sugar monitoring. Not approved for carcinoid or VIPoma. Typically a step-up option, not a first switch.

Fifth Option: Mycapssa (Oral Octreotide) — For Acromegaly Maintenance Only

Mycapssa is the only FDA-approved oral form of octreotide. It's a delayed-release capsule approved for long-term maintenance treatment in acromegaly patients who have already responded to and tolerated injectable octreotide or lanreotide. If you're on Sandostatin LAR for acromegaly and your condition is well-controlled, Mycapssa may be an option to discuss with your endocrinologist.

Pros: No injections. More convenient for patients.

Cons: Costs $8,000–$10,000/month. Only approved for acromegaly (not carcinoid or VIPoma). Requires prior response to injectable octreotide before use.

Sixth Option: Pegvisomant (Somavert) — For Acromegaly Only

Pegvisomant is a growth hormone receptor antagonist — it works differently from somatostatin analogs. Instead of suppressing GH secretion, it blocks GH from binding to its receptor, reducing IGF-1 levels. It's FDA-approved for acromegaly in patients with an inadequate response to surgery and/or radiation and who are not controlled with SSA therapy. Not an option for carcinoid syndrome or VIPoma.

Important: Never Switch on Your Own

Any switch from Sandostatin to an alternative requires your doctor's guidance. The dosing, monitoring, and insurance prior authorization steps are different for each alternative. Do not stop Sandostatin or change your dose without consulting your endocrinologist or oncologist first.

Bottom Line

When Sandostatin is unavailable, your best first step is always to try locating it through medfinder or other pharmacy-finding tools. If that doesn't work, talk to your doctor about bridging with immediate-release octreotide or switching to lanreotide. Clinical evidence supports comparable efficacy for most patients, and your prescriber can guide a safe and smooth transition.